---
title: "Psilocybin (COMP360) in Treatment-resistant depression: Effects of other drugs"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: Effects of other drugs. Topics: Regulatory summary of interactions with antidepressants and lithium, SSRIs and SNRIs: attenuation of psilocybin effects in survey reports, Escitalopram pretreatment before psilocybin 25 mg in healthy participants, Ongoing SSRI treatment with COMP360 25 mg in treatment-resistant depression, and 6 further topics. 10 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description/effects-of-other-drugs"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: Effects of other drugs

<a id="heading-2.1.2.9.1"></a>

## 2.1.2.9.1 Effects of Other Drugs on Psilocybin

<a id="topic-2.1.2.9.1-1"></a>

### Regulatory summary of interactions with antidepressants and lithium

> “Use of selective serotonin reuptake inhibitors, serotonin/norepinephrine reuptake inhibitors, or monoamine oxidase inhibitors for 3 weeks or more may reduce the subjective effects of psychedelic drugs.”
> “Use of tricyclic antidepressants or lithium for 3 weeks or more may potentiate the subjective effects of psychedelic drugs, creating a potential psychiatric safety concern.”
> “Use of selective serotonin reuptake inhibitors, serotonin/norepinephrine reuptake inhibitors, or monoamine oxidase inhibitors for less than 3 weeks may also potentiate the subjective effects of psychedelic drugs.”

Source: [FDA psychedelic drugs guidance (2026)](https://www.fda.gov/media/169694/download)

<a id="topic-2.1.2.9.1-2"></a>

### SSRIs and SNRIs: attenuation of psilocybin effects in survey reports

> “In reports (n = 611) of taking mushrooms with an antidepressant, probabilities [95% CI] of weaker than expected drug effects were 0.47 [0.41-0.54] (selective serotonergic reuptake inhibitors, SSRIs), 0.55 [0.44-0.67] (serotonin norepinephrine reuptake inhibitors, SNRIs) and 0.29 [0.2-0.39] (bupropion).”
> “SSRI/SNRIs appear to weaken psilocybin drug effects relative to a non-serotonergic antidepressant.”
> “This dampening effect may last as long as 3 months following antidepressant discontinuation.”

Source: [Gukasyan et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37291890/)

<a id="topic-2.1.2.9.1-3"></a>

### Escitalopram pretreatment before psilocybin 25 mg in healthy participants

> “Pretreatment consisted of 10 mg escitalopram daily for 7 days, followed by 20 mg daily for 7 days, including the day of psilocybin administration, or 14 days of placebo pretreatment before psilocybin administration.”
> “Escitalopram pretreatment had no relevant effect on positive mood effects of psilocybin but significantly reduced bad drug effects, anxiety, adverse cardiovascular effects, and other adverse effects of psilocybin compared with placebo pretreatment.”
> “Escitalopram did not alter the pharmacokinetics of psilocin.”
> “Further studies are needed with a longer antidepressant pretreatment time and patients with psychiatric disorders to further define interactions between antidepressants and psilocybin.”

Source: [Becker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9299061/)

<a id="topic-2.1.2.9.1-4"></a>

### Ongoing SSRI treatment with COMP360 25 mg in treatment-resistant depression

> “There were meaningful improvements in depression severity from Baseline to Week 3, indicating that ongoing SSRI treatment did not inhibit the therapeutic potential of psilocybin.”
> “Taken together, these findings suggest that the pharmacological interactions necessary for psilocybin to take effect are not meaningfully compromised by SSRIs”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-2.1.2.9.1-5"></a>

### Recent antidepressant discontinuation before COMP360 in the phase 2b trial

> “Antidepressant drug discontinuation was not related to worsening of depression severity before Baseline.”
> “Psilocybin treatment efficacy and the subjective psychedelic experience did not appear to be compromised by antidepressant drug discontinuation.”

Source: [Marwood et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39427449/)

<a id="topic-2.1.2.9.1-6"></a>

### Chronic antidepressant exposure and 5-HT2A receptors in preclinical studies

> “More convincingly, chronic administration of antidepressant drugs, including a selective serotonin reuptake inhibitor (SSRI), reduced the head-twitch response, a stereotypic behavior exhibited by rodents in response to 5-HT2A agonizts and also downregulated 5-HT2A receptors, which are considered essential for the subjective psychedelic effects of psilocybin”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-2.1.2.9.1-7"></a>

### Lithium and seizures

> “They found that 2 of the 6 reports of lithium plus psilocybin resulted in seizures.”
> “None of the 10 reports of lamotrigine plus psilocybin resulted in seizures.”

Source: [Sarparast et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9177763/)

<a id="topic-2.1.2.9.1-8"></a>

### Monoamine oxidase inhibitors

> “Inhibition of psilocin inactivation by MAO could potentially augment the metabolic pathway catalyzed by CYP2D6, thereby altering the pharmacodynamics of psilocybin therapy.”
> “Moreover, glucuronidation of psilocin would likely continue to be the predominant metabolic pathway, rendering MAO inhibition potentially less important.”

Source: [Thomann et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11089204/)

<a id="topic-2.1.2.9.1-9"></a>

### UGT1A9 and UGT1A10 inhibitors and estradiol

> “Diclofenac and probenecid are examples of UGT1A9/10 inhibitors that may hypothetically alter psilocybin metabolism if co-ingested; however, there is no evidence to confirm this hypothesis beyond shared metabolism.”
> “There are few pharmacologic agents that influence UGT1A9 and UGT1A10”
> “This suggests that hormone replacement therapy, oral contraceptives, and cyclical hormonal changes may affect the metabolism of psilocybin, highlighting the need for more inclusive research.”

Source: [Sarparast et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9177763/)

<a id="topic-2.1.2.9.1-10"></a>

### Antipsychotics and 5-HT2A receptor antagonists

> “Haloperidol pretreatment reduced psilocybin effects on the Oceanic boundlessness, measures of derealisation and depersonalisation phenomena but increased anxiety without any effects on visual hallucinations or delayed response tasks.”
> “Risperidone pretreatment attenuated the effects of psilocybin in a dose-dependent manner.”
> “Ketanserin pretreatment blocked psilocybin effects in a dose-dependent manner on the delayed response task and Altered State of Consciousness Rating scale.”
> “Except for a few case reports, no serious adverse drug events were described in the included studies.”

Source: [Halman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10851641/)

Additional sources: [Nayak et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34348413/)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
